Evaluation of Technetium Tc 99m Tilmanocept Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT/CT Imaging

Trial Profile

Evaluation of Technetium Tc 99m Tilmanocept Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT/CT Imaging

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2016

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Kaposi's sarcoma
  • Focus Diagnostic use
  • Sponsors Navidea Biopharmaceuticals
  • Most Recent Events

    • 04 Jun 2015 According to Navidea Biopharmaceuticals media release, the data from this trial will be presented at 18th international workshop on Kaposis Sarcoma HerpesVirus (KSHV) and Related Agents in Hollywood, Florida.
    • 03 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Apr 2015 Complete results will be presented in the coming months, as per Navidea Biopharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top